Improvement in Cognitive Processing Speed With Ofatumumab in Patients With Relapsing Multiple Sclerosis

被引：1
|
作者：
Benedict, Ralph
Penner, Iris Katharina
Cutter, Gary
Kappos, Ludwig
Coyle, Patricia
Piani-Meier, Daniela
Azmon, Amin
Boer, Ibolya
Su, Wendy
Cohen, Jeffrey
机构：
来源：
NEUROLOGY | 2023年 / 100卷 / 17期
关键词：
D O I：
10.1212/WNL.0000000000203201
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P6-3.005
引用
收藏
页数：4
相关论文
共 50 条
  • [31] Ozanimod-treated patients exhibited improvements in cognitive processing speed in the phase 3 SUNBEAM trial of relapsing multiple sclerosis (RMS)
    Deluca, J.
    Huang, D.
    Cohen, J. A.
    Cree, B. A. C.
    Chen, Y.
    Campagnolo, D.
    Sheffield, J. K.
    Comi, G.
    Kappos, L.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 263 - 264
  • [32] Author response: Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study
    Bar-Or, Amit
    Grove, Richard A.
    Tolson, Jerry M.
    Derosier, Frederick J.
    Lopez, Monica C.
    Kavanagh, Sarah T.
    Miller, Aaron E.
    NEUROLOGY, 2019, 92 (11) : 543 - 543
  • [33] Long-term Effect of Ofatumumab on Serum Immunoglobulin Levels in Patients With Relapsing Multiple Sclerosis
    Wiendl, Heinz
    de Seze, Jerome
    Bar-Or, Amit
    Correale, Jorge
    Cross, Anne
    Derfuss, Tobias
    Selmaj, Krzysztof
    Winthrop, Kevin
    Giacomini, Paul
    Sacca, Francesco
    Hu, Xixi
    Sullivan, Roseanne
    Jehl, Valentine
    Boer, Ibolya
    Bhatt, Alit
    Hauser, Stephen
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 612 - 613
  • [34] Baseline Cognition and Magnetic Resonance Imaging Measures of Patients With Relapsing Multiple Sclerosis in ENLIGHTEN: a Study of the Effect of Ozanimod on Cognitive Processing Speed
    DeLuca, J.
    Riolo, J. V.
    Cheng, C.
    Naismith, R. T.
    Wray, S.
    Bass, A. D.
    Fox, E.
    Riser, E.
    Chaudhry, B.
    Silva, D.
    Zivadinov, R.
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 49 - 50
  • [35] Change in cognitive processing speed is associated with cortical grey matter and thalamic volume loss in patients with relapsing-remitting multiple sclerosis
    Benedict, R. H.
    Arnold, D. L.
    Rose, J.
    Cohan, S.
    Lynch, S. G.
    Kappos, L.
    Havrdova, E. K.
    Khatri, B.
    Su, R.
    Naylor, M. L.
    Kieseier, B. C.
    Giovannoni, G.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 177 - 178
  • [36] COST-EFFECTIVENESS OF OFATUMUMAB IN TREATMENT OF RELAPSING MULTIPLE SCLEROSIS IN TURKEY
    Tatar, M.
    Yarci, B.
    Akdemir, A. C.
    Olmez, C.
    Tinaz, E.
    Turanli, M.
    VALUE IN HEALTH, 2023, 26 (12) : S148 - S148
  • [37] COST-EFFECTIVENESS OF OFATUMUMAB VERSUS OCRELIZUMAB IN PATIENTS WITH ACTIVE RELAPSING MULTIPLE SCLEROSIS IN PORTUGAL
    Goncalves, N.
    Esparteiro, J.
    Machado, M.
    Ferreira, C.
    Guerreiro, T.
    VALUE IN HEALTH, 2022, 25 (12) : S78 - S78
  • [38] Ofatumumab Dose Selection in Pediatric Population with Relapsing Multiple Sclerosis (RMS)
    Skataric, Maja
    Savelieva, Marina
    Pigeolet, Etienne
    Leppert, David
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2018, 45 : S86 - S86
  • [39] Reader response: Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study
    Kearney, Hugh
    NEUROLOGY, 2019, 92 (11) : 542 - 543
  • [40] Editors' note: Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study
    Lewis, Ariane
    Galetta, Steven
    NEUROLOGY, 2019, 92 (11) : 542 - 542
12345